DSE:ORIONINFU

Orion Infusion Limited research

Reports on Orion Infusion Limited

Company · Analysis · 31 Oct 2026
Orion Infusion: FY2025 sales fell 20% to BDT 665m and 9M FY2026 sales fell a further 3.5%, while the shares trade at 131x trailing earnings
Bangladesh's largest dedicated IV-fluid maker has not grown in ten years: revenue was BDT 730m in FY2016 and BDT 665m in FY2025. ROE has stayed at 11-16%, a BDT 306m bank line costs 12.9%, and capacity use fell to 75%. A BDT 205m line expansion, to be funded internally, is due to finish in December 2026.

Orion Infusion Limited (OIL) makes intravenous (IV) fluids and other injectable "parenteral" products at a single plant and sells them to hospitals, clinics and pharmacies across Bangladesh. It is a member of the Orion Group, listed on the Dhaka Stock Exchange in 1994, and has…

Peer comparisons and industry research covering Orion Infusion Limited

Company · DSE:IBP · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Indo-Bangla Pharmaceuticals: revenue of BDT 184.2m in FY2025 against BDT 866.1m in FY2020, a qualified audit with a going-concern paragraph, and 9M FY2026 profit of BDT 2.8m
The Barishal-based tablet and capsule maker reported net losses of BDT 41.0m in FY2024 and BDT 36.8m in FY2025. Its auditor qualified the FY2025 accounts on four bases and reported a material uncertainty on going concern. Nine-month FY2026 revenue was BDT 134.8m, against BDT 76.9m a year earlier.

Indo-Bangla Pharmaceuticals PLC (IBP) makes and sells human-health medicines, excluding antibiotics, from a single factory at College Road, Barishal. The business traces to Indo-Pak Pharmaceutical Works, founded in 1954; it was privatised in 1982, incorporated as a private limited company on 18-Jun-2014, converted to a…

Company · DSE:PHARMAID · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Pharma Aids: FY2025 net sales of BDT 438m, 9M FY2026 sales up 17.6% and profit up 28.1%, sponsors at 19.38%
Bangladesh's listed maker of neutral glass ampoules for drug companies: seven years of filings, a 30.3% gross margin, BDT 27.3m of borrowings at June 2025, an auditor's opinion worded 'except for', and FY2026 results due to the board on 3-Nov-2026.

Pharma Aids Limited makes one product family: neutral glass ampoules, the small sealed glass containers that injectable medicines are filled into. It sells all of its output to pharmaceutical companies in Bangladesh in local currency and does not export; its main raw materials, neutral glass…

Company · DSE:TECHNODRUG · Pharmaceuticals & healthcare · Analysis · 31 Oct 2026
Techno Drugs: FY2026 EPS of BDT 1.51 against 1.76, and BDT 129.8m of overdue loan interest disclosed in October 2026
The contraceptive supplier to the government reported FY2026 EPS of BDT 1.51 against 1.76, finance expenses at 11.2% of nine-month revenue, and told DSE in October 2026 that BDT 12.98 crore of loan interest was overdue; the board kept a 10% cash dividend for non-sponsor holders.

Techno Drugs Ltd. (TDL) makes human and veterinary medicines at two plants, at Satirpara in Narsingdi and at B.K. Bari, Mirzapur in Gazipur. It describes itself as the biggest supplier of injectable hormonal medicines to the government of Bangladesh, the fifth maker of contraceptive implants…

All Bangladesh research →